title: Biosimilars of low-molecular-weight heparin products: fostering competition or reducing 'biodiversity'?
abstract: The term 'biosimilars' is used to qualify products developed to be similar to an original biological drug. Biosimilars are much more complicated to develop than a generic version of small-molecule drugs and this is especially true for low-molecular-weight heparins (LMWHs). Evidence on the antithrombotic management of acute coronary syndromes (ACS) showed that the introduction into the market of biosimilars approved on the basis of simple biological criteria, without robust data from comparative clinical trials, may be hazardous. Moreover, the mixtures of LMWH polysaccharide chains, some immunoallergic properties and potential contamination during the extraction process raise safety concerns. As was the case for the biosimilar erythropoietin, there is the risk that only copies of the most commercially successful LMWHs will be marketed, thus jeopardizing the 'biodiversity' now ensured by the presence of several LMWHs, each with unique features that support the use of an individual LMWH as first-choice therapy in certain categories of patients.
authors.affiliation: Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Harenberg
authors.affiliation: Department of Medicine, Vimercate Hospital Azienda Ospedaliera di Desio e Vimercate, Vimercate, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Cimminiello
authors.affiliation: Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Agnelli
authors.affiliation: Department of Clinical and Experimental Medicine, Federico II University Hospital, Naples, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Di Minno
authors.affiliation: Department of Medicine, Vimercate Hospital Azienda Ospedaliera di Desio e Vimercate, Vimercate, Italy.
authors.forename: H
authors.initials: H
authors.lastname: Polo Friz
authors.affiliation: Department of Cardiothoracic and Vascular Sciences, Clinica Medica 2, University of Padua, Padua, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Prandoni
authors.affiliation: Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Scaglione
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics*; D059451:Biosimilar Pharmaceuticals / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics*; D016527:Drug Costs; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D004345:Drug Industry / Q000191:economics; D004465:Economic Competition; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D061214:Patient Safety; D018570:Risk Assessment; D012307:Risk Factors; D013810:Therapeutic Equivalency
chemical_list: D000925:Anticoagulants; D059451:Biosimilar Pharmaceuticals; D006495:Heparin, Low-Molecular-Weight
keywords: biosimilar pharmaceuticals; evidence-based practise; low-molecular-weight heparin; therapeutic equivalency; venous thromboembolism